Multiple Etiology Dementias: Determine impact of cognitive screening in midlife

AD-Related Dementias Focus

Evaluate the benefits, burdens, and harms of screening for cognitive impairment in older adults in the absence of a patient, care partner or clinician report of cognitive, behavioral, or functional changes.

2028 RFA-NS-22-009: Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and Health Equity, Pragmatic Clinical Trials (U01 Clinical Trial Required) RFA-NS-25-014: Mechanisms of Cognitive Fluctuations in ADRD Populations (R01 - Clinical Trial Optional) 9.N To Be Initiated Determining the value of screening for clinically relevant cognitive impairment in the absence of a cognitive complaint. DN ADRD Summit 2016: Multiple Etiology Dementias (MED) Focus Area 3: Determining the Role for Screening for Cognitive Dysfunction, Milestone 6 ADRD Summit 2022: Multiple Etiology Dementias (MED) Milestone 2, Priority 4 Biomarkers Projects funded under RFA-NS-22-009 DetectCID

• At least one real-world clinical practice study to determine the benefits, burdens, and harms of screening for cognitive impairment including dementia in older adults. This trial is to be powered to answer the question in at least two populations that experience health disparities.